氨曲南/阿维巴坦体外药物敏感性测试EUCAST折点的适用性研究

Study on applicability of EUCAST breakpoints for aztreonam-avibactam in vitro antimicrobial susceptibility testing

  • 摘要:
    目的 采用不同药敏试验方法评估氨曲南/阿维巴坦对产金属类碳青霉烯酶肠杆菌目细菌(CRE)的体外抗菌活性, 并基于欧洲抗菌药物敏感性试验委员会(EUCAST)推荐的最新折点, 分析不同方法判定结果的一致性及其临床适用性。
    方法 收集2019年1月-2023年3月北京朝阳医院临床标本中分离的亚胺培南或美罗培南耐药的肠杆菌目细菌, 经胶体金法和Sanger测序法确认后, 选取产金属酶的CRE菌株作为研究对象。采用微量肉汤稀释法测定氨曲南单药及氨曲南/阿维巴坦复合制剂的最小抑菌浓度(MIC)值, 并同时采用纸片扩散法和浓度梯度法检测菌株对氨曲南/阿维巴坦的体外药物敏感性。
    结果 本研究纳入的87株产金属酶CRE中大肠埃希菌占比最高(44.83%)。从酶型分布来看, NDM-5型占比最高(48.28%)。依据EUCAST最新折点, 微量肉汤稀释法测定的氨曲南/阿维巴坦耐药菌共6株(均为大肠埃希菌), 耐药率为6.90%(6/87);而纸片扩散法测得的耐药率高达22.99%(20/87), 且有14株菌的判定结果处于技术不确定/耐药区域, 导致结果解读困难。此外, 浓度梯度法与微量肉汤稀释法的分类一致率达98.85%。
    结论 氨曲南/阿维巴坦对产金属酶CRE具有较强的抗菌活性。根据EUCAST最新折点, 纸片扩散法药敏结果会有部分菌株分类判读结果解读困难, 应结合其他方法进一步验证。

     

    Abstract:
    OBJECTIVE To assess the in vitro antimicrobial activity of aztreonam-avibactam against metallo-β-lactamase (MBL)-producing carbapenem-resistant Enterobacteriaceae(CRE) using different antimicrobial susceptibility testing methods, evaluate the consistency of results based on the latest breakpoints recommended by European Committee on Antimicrobial Susceptibility Testing (EUCAST), and analyze the clinical applicability.
    METHODS The imipenem- or meropenem-resistant Enterobacteriaceae strains were isolated from the clinical specimens of Beijing Chaoyang Hospital from Jan. 2019 to Mar. 2023, MBL-producing CRE were selected after they were confirmed by colloidal gold immunoassay and Sanger sequencing as the study subjects. The minimum inhibitory concentrations (MICs) of single aztreonam and aztreonam-avibactam compounds were determined by using broth microdilution method. In addition, the disk diffusion method and the gradient diffusion method were employed to further detect the in vitro susceptibility to aztreonam-avibactam.
    RESULTS Among the 87 strains of MBL-producing CRE that were included in the study, Escherichia coli was the most common species, accounting for 44.83%. NDM-5 was the predominant carbapenemase type, detected in 48.28% of the isolates. According to the latest EUCAST breakpoints, 6 isolates were aztreonam-avibactam-resistant strains based on broth microdilution method, all of which were E. coli, and the resistance rate was 6.90% (6/87). However, the resistance rate that was determined by the disk diffusion method was significantly higher (22.99%, 20/87). Among these, 14 strains was within the area of technical uncertainty/resistant, making result interpretation difficult. In addition, the categorical agreement between the gradient diffusion method and the broth microdilution method reached up to 98.85%.
    CONCLUSIONS Aztreonam-avibactam has high antimicrobial activity against MBL-producing CRE. However, based on the latest EUCAST breakpoints, the antimicrobial susceptibility testing by the disk diffusion method results of some strains are hard to interpret. It is necessary to integrate with other methods for further validation.

     

/

返回文章
返回